|
|
|
|
|
|
|
|
|
|
|
|
|
|
Previous: APS HOLDING CORPORATION, S-4/A, 1996-06-12 |
Next: VIMRX PHARMACEUTICALS INC, DEFA14A, 1996-06-12 |
IN ACCORDANCE WITH RULE 202 OF REGULATION
ST, THIS FORM 10Q IS BEING FILED IN PAPER
PURSUANT TO A CONTINUING HARDSHIP
EXEMPTION.
_____________________________________________
SECURITIES AND EXCHANGE
COMMISSION
Washington, D.C. 20549
_______________________
FORM 10-Q
X QUARTERLY REPORT PURSUANT TO SECTION 13
OR
15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the Quarterly Period Ended March 31, 1996
OR
TRANSITION REPORT PURSUANT TO SECTION 13
OR
15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from____________to____________
Commission File No. 0-19153
_____________________
VIMRx PHARMACEUTICALS INC.
(Exact name of Registrant as specified in its Charter)
_____________________
Delaware<PAGE>
06-1192468<PAGE>
(State or other jurisdiction of<PAGE>
(I.R.S. Employer<PAGE>
incorporation or organization)<PAGE>
Identification No.)<PAGE>
1200 High Ridge Road, Stamford, Connecticut<PAGE>
06905<PAGE>
(Address of principal executive offices)
(Zip Code)<PAGE>
Registrant's telephone number, including area code: (203) 329-0811
Indicate by check mark whether the Registrant (1)
has filed all reports
required to be filed by Section 13 or 15 (d) of the Securities
Exchange Act of 1934
during the preceding 12 months (or for such shorter period that the
Registrant was
required to file such reports), and (2) has been subject to such
filing requirements for
the past 90 days.
Yes X No
The aggregate number of Registrant's shares
outstanding on
May 3, 1996 was 28,644,318 shares of Common Stock, $.001 par
value.
__________________________________________
Page 1 of 10 Pages<PAGE>
VIMRx PHARMACEUTICALS INC.
INDEX
PART I - FINANCIAL INFORMATION Page
Item 1. Financial Statements:
Consolidated
Balance Sheets as of March 31, 1996
(unaudited).December 31, 1995
and...................... 3
Consolidated Statements of Operations (unaudited)
for the
Three Months Ended March 31, 1996 and 1995,
and for the Period from Inception through
March 31,
1996............................................. 4
Consolidated
S
tatements of Cash Flows (unaudited)
for the
Three Months Ended March 31, 1996 and 1995,
and for the Period from Inception through
March 31,
1996............................................. 5
Notes to Finan
cial Statements
(unaudited)....................... 6
Item 2.
Management's Discussion and Analysis of Financial
Condition and Results of
Operations......................... 7
PART II - OTHER INFORMATION
Item 1. Legal
Proceedings.. 9
Item 2. Changes in
Securities........... 9
Item 3. Defaults upon Senior
Securities...................................... 9
Item 4.
Submission of Matters to a Vote of Security
Holders........... 9
Item 5. Other
Information. 9
Item 6. Exhibits and Reports on Form
8-K.................................. 9
SIGNATURE.......................... 11
<PAGE>
PART I - FINANCIAL INFORMATION
Item 1. Financial Statements
VIMRx PHARMACEUTICALS INC.
(a development stage enterprise)
CONSOLIDATED BALANCE SHEETS
March 31,
December 31,
1996
1995
(unaudited)
ASSETS
Current assets:
Cash and cash equivalents
$ 3,100,232
$ 2,218,970
Deferred finance cost
232,500
310,000
Other current assets
72,895
96,115
Total current assets
|
|